ImmunityBio Inc
IBRXHealthcare|Biotechnology|USA
$8.23
-0.65 (-7.33%)
Clinical Trials (89)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06745908 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In | NSCLC Stage IV | P3 | Recruiting | 507 | RCT, Open-label | N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor |
| NCT03022825 QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | Bladder Cancer | P2P3 | Active | 190 | Open-label | N-803 and BCG, N-803 |
| NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | Pancreatic Cancer | P2 | Active | 328 | RCT, Open-label | N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Irinotecan liposome |
| NCT06061809 N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | Glioblastoma | P2 | Active | 34 | RCT, Open-label | Bevacizumab, PD-L1 t-haNK, N-803 |
| NCT06800963 ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | NMIBC | P1P2 | Recruiting | 40 | Open-label | Intravesical Recombinant Mycobacterium (rMBCG) |
| NCT06710288 A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | Platinum-resistant Ovarian Cancer | P2 | Recruiting | 20 | Open-label | Gemcitabine, N-803, M-CENK |
| NCT06239220 PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | P2 | Recruiting | 25 | Open-label | PD-L1 t-haNK, Cetuximab, NAI |
| NCT07125872 Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | Relapsed B-Cell Non Hodgkin Lymphoma | P2 | Recruiting | 20 | Open-label | CD19 t-haNK- IV Administration |
| NCT03228667 QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | Non-Small Cell Lung Cancer, Small Cell Lung Cancer | P2 | Active | 40 | Open-label | N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab |
| NCT02782546 Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | Acute Myeloid Leukemia | P2 | Active | 60 | Open-label | Tacrolimus, Mycophenolate mofetil, G-CSF, ALT-803 |
| NCT07123727 A Study to Examine Anktiva for the Treatment of COVID-19. | Long COVID, Long COVID Syndrome | P2 | Recruiting | 40 | Open-label | Anktiva |
| NCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19. | Long COVID | P2 | Recruiting | 20 | Open-label | N-803 (IL-15 Superagonist) |
| NCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer | P1P2 | Active | 369 | RCT, Open-label | BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation) |
| NCT07355205 First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | P1P2 | Recruiting | 26 | Open-label | Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept |
| NCT07556757 A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | B-ALL, Leukemia | P1 | Recruiting | 10 | Open-label | CD19 t-haNK |
| NCT06334991 Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma Refractory/ Relapsed | P1 | Active | 20 | Open-label | CD19 t-haNK |
| NCT04340596 Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption | HIV Infection | P1 | Active | 118 | RCT, Open-label | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 |
| NCT05976828 IBRX-042 In Participants With HPV-Associated Tumors | HPV-Related Carcinoma | P1 | Active | 12 | Open-label | IBRX-042 |
| NCT05618925 Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | Non Hodgkin's Lymphoma Refractory/Relapsed | P1 | Recruiting | 20 | RCT, Open-label | N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab |
| NCT04898543 QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Metastatic Solid Tumor | P1 | Active | 50 | Open-label | M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B) |
| NCT05981131 Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) | Non Muscle Invasive Bladder Cancer | Active | 6 | — | N803 plus Bacillus Calmette-Guerin (BCG) | |
| NCT07551544 ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | NMIBC | P3 | Withdrawn | — | RCT, Open-label | BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) |
| NCT07524257 Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | P3 | Withdrawn | — | RCT, Open-label | Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin, Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous), Nab-paclitaxel OR Paclitaxel OR Docetaxel (squamous), Pemetrexed (nonsquamous) |
| NCT02049905 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | P3 | Completed | 433 | RCT, Open-label | Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) |
| NCT07492875 Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia | Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) | P3 | Withdrawn | — | RCT, Single-blind | Nogapendekin alfa inbakicept (NAI), agenT-797 |
| NCT06022224 A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL | COVID-19 | P2P3 | Terminated | 35 | RCT, Double-blind | hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline) |
| NCT03520686 Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P3 | Terminated | 102 | RCT, Open-label | NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel |
| NCT03169764 QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Head and Neck Squamous Cell Carcinoma | P1P2 | Withdrawn | — | Open-label | Avelumab, Bevacizumab, Capecitabine, Cetuximab, Cisplatin, cyclophosphamide, 5-Fluorouracil (5-FU), fulvestrant, leucovorin, nab-paclitaxel, nivolumab, Lovaza, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK |
| NCT02029430 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | Kaposi's Sarcoma, HIV Positive | P2 | Completed | 15 | RCT, Open-label | 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin |
| NCT02235701 Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | P1P2 | Completed | 70 | RCT, Open-label | 170 mg/m2 aldoxorubicin, 250 mg/m2 aldoxorubicin |
| NCT03136406 QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Pancreatic Cancer | P1P2 | Terminated | 3 | Open-label | Cyclophosphamide, Oxaliplatin, Capecitabine, 5-Fluorouracil, Leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK for Infusion, ETBX-011, GI-4000 |
| NCT03574649 QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Withdrawn | — | RCT, Open-label | Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin |
| NCT02465957 QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma | P2 | Terminated | 7 | Open-label | aNK (NK-92), aNK (NK-92) + N-803 |
| NCT06765902 Immunotherapy Before and After Surgery | High-risk Prostate Cancer | P2 | Withdrawn | — | Open-label | N-803, ETBX-071, M-CENK |
| NCT07628062 Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | P2 | Not Yet Recruiting | 70 | RCT, Open-label | Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel, Cisplatin |
| NCT03563170 QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | P1P2 | Withdrawn | — | RCT, Open-label | ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803 |
| NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | P2 | Not Yet Recruiting | 20 | RCT, Open-label | N-803 and BCG, N-803 and Gemcitabine |
| NCT07477366 Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma | P2 | Not Yet Recruiting | 20 | Open-label | CD19 t-haNK- IV Administration, N-803, rituximab |
| NCT01514188 Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | P2 | Completed | 126 | RCT, Open-label | INNO-206, Doxorubicin |
| NCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | P2 | Withdrawn | — | Open-label | Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) |
| NCT03387085 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Triple Negative Breast Cancer | P1P2 | Terminated | 9 | Open-label | Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel |
| NCT04843722 COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines | Covid19 | P1P2 | Withdrawn | — | RCT, Double-blind | hAd5-S-Fusion+N-ETSD vaccine |
| NCT02200757 Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | Metastatic Small Cell Lung Cancer | P2 | Completed | 135 | RCT, Open-label | Aldoxorubicin, Topotecan |
| NCT03647423 QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | Chordoma, Unresectable Malignant Neoplasm | P1P2 | Withdrawn | — | RCT, Open-label | Aldoxorubicin Hydrochloride, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, Avelumab, Cetuximab, Cyclophosphamide |
| NCT03197571 QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Urothelial Carcinoma | P1P2 | Withdrawn | — | Open-label | avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5Fluorouracil (5-FU), fulvestrant, leucovorin, nab-paclitaxel, Lovaza, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK |
| NCT03586869 QUILT-3.080: NANT Pancreatic Cancer Vaccine | Pancreatic Cancer | P1P2 | Terminated | 3 | Open-label | Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Oxaliplatin, Avelumab |
| NCT03169738 QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | Non-small Cell Lung Cancer | P1P2 | Withdrawn | — | Open-label | avelumab, Bevacizumab, Capecitabine, Cisplatin, cyclophosphamide, 5-Fluorouracil (5-FU), fulvestrant, leucovorin, nab paclitaxel, nivolumab, Lovaza, Oxaliplatin, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK |
| NCT04927884 A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | Advanced Triple Negative Breast Cancer | P1P2 | Terminated | 3 | Open-label | N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide |
| NCT03387111 QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | Squamous Cell Carcinoma | P1P2 | Terminated | 4 | Open-label | Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, N-803 |
| NCT01580397 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | P2 | Completed | 15 | Open-label | INNO-206 |
| NCT03169777 QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | Colorectal Cancer | P1P2 | Withdrawn | — | Open-label | avelumab, bevacizumab, capecitabine, cetuximab, Cyclophosphamide, 5-Fluorouracil (5-FU), fulvestrant, leucovorin, nab paclitaxel, nivolumab, Lovaza, oxaliplatin, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK |
| NCT03169790 QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | Non Hodgkin Lymphoma | P1P2 | Withdrawn | — | Open-label | avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-Fluorouracil (5-FU), leucovorin, nab-paclitaxel, Lovaza, Oxaliplatin, rituximab, ALT-803, ETBX-061, haNK |
| NCT03563144 QUILT-3.088: NANT Pancreatic Cancer Vaccine | Metastatic Pancreatic Cancer | P2 | Withdrawn | — | RCT, Open-label | Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Bevacizumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Oxaliplatin |
| NCT03197584 QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | Ovarian Cancer | P1P2 | Withdrawn | — | Open-label | Avelumab, Bevacizumab, Capecitabine, Cyclophosphamide, 5-fluorouracil, Fulvestrant, Leucovorin, Paclitaxel, omega-3 acid ethyl esters, Oxaliplatin, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, haNK® |
| NCT01898793 Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Leukemia, Myeloid, Acute | P1P2 | Terminated | 89 | Open-label | Fludarabine, Cyclophosphamide, Cytokine-induced killer cells, IL-2, ALT-803 |
| NCT06765954 Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. | High-risk Prostate Cancer | P2 | Withdrawn | — | Open-label | N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) |
| NCT03853317 QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | Merkel Cell Carcinoma | P2 | Terminated | 9 | Open-label | Avelumab, N-803, haNK™ |
| NCT02014844 Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | Glioblastoma | P2 | Completed | 28 | RCT, Open-label | 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin |
| NCT03329248 QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Pancreatic Cancer | P1P2 | Terminated | 6 | Open-label | ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin |
| NCT07578558 NAI for Sepsis With Persistent Lymphopenia | Sepsis, Septic Shock | P2 | Not Yet Recruiting | 50 | RCT, Open-label | Nogapendekin alfa inbakicept (NAI) |
| NCT04845191 COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines | Covid19 | P1P2 | Withdrawn | — | RCT, Double-blind | hAd5-S-Fusion+N-ETSD vaccine |
| NCT03387098 QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Pancreatic Cancer | P1P2 | Terminated | 4 | Open-label | Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin |
| NCT03554109 QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Triple Negative Breast Cancer (TNBC) | P2 | Withdrawn | — | RCT, Open-label | Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel |
| NCT03175666 QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | Triple Negative Breast Cancer | P1P2 | Withdrawn | — | Open-label | avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-paclitaxel, Lovaza, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK |
| NCT05304936 HCW9218 for Advanced Pancreatic Cancer | Advanced Pancreatic Carcinoma | P1P2 | Completed | 21 | Open-label | HCW9218, Gemcitabine (GEM), Nab-paclitaxel |
| NCT05370040 THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines | COVID-19 | P1P2 | Terminated | 60 | RCT, Double-blind | AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine |
| NCT03563157 QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Colorectal Cancer Metastatic, mCRC | P1P2 | Terminated | 2 | RCT, Open-label | Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib |
| NCT03167177 QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | Melanoma | P1P2 | Withdrawn | — | Open-label | Avelumab, Bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-fluorouracil, Leucovorin, nab-paclitaxel, Nivolumab, omega-3-acid ethyl esters, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, haNK |
| NCT05007769 Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | Non-small Cell Lung Cancer, Non-small Cell Carcinoma | P2 | Withdrawn | — | Open-label | Ramucirumab, Atezolizumab, N-803 |
| NCT03167164 QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | Merkel Cell Carcinoma | P1P2 | Withdrawn | — | Open-label | Avelumab, Bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-fluorouracil, Leucovorin, nab-Paclitaxel, omega-3-acid ethyl esters, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK |
| NCT00900809 QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Completed | 7 | Open-label | Neukoplast™ (NK-92) |
| NCT04050709 QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | Locally Advanced Solid Tumor, Metastatic Cancer | P1 | Completed | 16 | Open-label | PD-L1 t-haNK |
| NCT01673438 Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Completed | 15 | Open-label | aldoxorubicin |
| NCT04397796 Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | COVID | P1 | Terminated | 4 | RCT, Double-blind | BM-Allo.MSC, Placebo |
| NCT04052061 QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | Diffuse Large B Cell Lymphoma, Large-cell Lymphoma | P1 | Withdrawn | — | Open-label | CD19 t-haNK |
| NCT06040918 Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis | Healthy Subjects | P1 | Completed | 10 | Open-label | N-803 |
| NCT07049432 N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | B-cell Non Hodgkin Lymphoma | P1 | Withdrawn | — | Open-label | N803 |
| NCT03027128 QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | Solid Tumor | P1 | Completed | 6 | Open-label | haNK™ for Infusion |
| NCT01337505 Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | Malignant Solid Tumour | P1 | Completed | 24 | Open-label | INNO-206 |
| NCT04710303 COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults | Covid19 | P1 | Completed | 41 | Open-label | hAd5-S-Fusion+N-ETSD vaccine |
| NCT04732468 COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA | Covid19 | P1 | Terminated | 28 | Open-label | hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule) |
| NCT02235688 Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors | Metastatic Solid Tumors | P1 | Completed | 30 | Open-label | aldoxorubicin, aldoxorubicin, aldoxorubicin, gemcitabine |
| NCT04591717 COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers | COVID-19 | P1 | Completed | 34 | Open-label | hAd5-S-Fusion+N-ETSD vaccine |
| NCT01706835 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 18 | Open-label | aldoxorubicin |
| NCT07217496 N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | Metastatic Urothelial Carcinoma, Urothelial Carcinoma | P1 | Withdrawn | — | Open-label | Nogapendekin Alfa Inbakicept (N803), Enfortumab Vedotin (EV), Pembrolizumab |
| NCT04385849 Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 | COVID-19 | P1 | Terminated | 1 | RCT, Double-blind | N-803 |
| NCT07488884 Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer | Pancreatic Cancer Resectable, Pancreatic Cancer | P1 | Not Yet Recruiting | 30 | Open-label | Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101), Nab paclitaxel / gemcitabine |
| NCT06810141 ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer | NMIBC | AVAILABLE | — | — | rMBCG | |
| NCT06956547 Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy | Lymphopenia | AVAILABLE | — | — | nogapendekin-alfa inbakicept |